Graphene Oxide‐Cyclic R10 Peptide Nuclear Translocation Nanoplatforms for the Surmounting of Multiple‐Drug Resistance,Advanced Functional Materials

当前位置： X-MOL 学术 › Adv. Funct. Mater. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Graphene Oxide‐Cyclic R10 Peptide Nuclear Translocation Nanoplatforms for the Surmounting of Multiple‐Drug Resistance
Advanced Functional Materials ( IF 18.5 ) Pub Date : 2020-06-26 , DOI: 10.1002/adfm.202000933
Zhaoxu Tu _{1,

2} , Ievgen S. Donskyi _{2,

3} , Haishi Qiao ₁ , Zhonglin Zhu ₁ , Wolfgang E. S. Unger ₃ , Christian P. R. Hackenberger _{4,

5} , Wei Chen ₁ , Mohsen Adeli _{2,

6} , Rainer Haag ₂

Affiliation

Multidrug resistance resulting from a variety of defensive pathways in cancer has become a global concern with a considerable impact on the mortality associated with the failure of traditional chemotherapy. Therefore, further research and new therapies are required to overcome this challenge. In this work, a cyclic R10 peptide (cR₁₀) is conjugated to polyglycerol‐covered nanographene oxide to engineer a nanoplatform for the surmounting of multidrug resistance. The nuclear translocation of the nanoplatform, facilitated by cR₁₀ peptide, and subsequently, a laser‐triggered release of the loaded doxorubicin result in efficient anticancer activity confirmed by both in vitro and in vivo experiments. The synthesized nanoplatform with a combination of different features, including active nucleus‐targeting, high‐loading capacity, controlled release of cargo, and photothermal property, provides a new strategy for circumventing multidrug resistant cancers.

中文翻译：

氧化石墨烯环R10肽核易位纳米平台克服多重耐药性。

由癌症的多种防御途径引起的多药耐药性已成为全球关注的问题，对与传统化学疗法失败相关的死亡率产生重大影响。因此，需要进一步的研究和新的疗法来克服这一挑战。在这项工作中，将环状R10肽（cR ₁₀）与聚甘油覆盖的纳米氧化石墨烯偶联，以构建纳米平台，以克服多重耐药性。cR ₁₀促进纳米平台的核易位肽，随后通过激光触发释放的阿霉素可导致有效的抗癌活性，这一点已在体外和体内实验中得到证实。合成的纳米平台具有多种不同特征，包括主动靶向核，高负载能力，货物的受控释放和光热特性，为绕开耐多药癌症提供了新策略。

更新日期：2020-08-26

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11